Daxor Corp
DXR
Company Profile
Business description
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. The company operates as a single business segment centered on the development, commercialization, and support of its proprietary blood volume analysis technology used by healthcare providers.
Contact
107 Meco Lane
Oak RidgeTN37830
USAT: +1 212 330-8500
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
750
Stocks News & Analysis
stocks
Chip stock selloff deepens in Asia, extends to Europe and US
The week’s tech stock rout continues despite strong earnings from TSMC and ASML.
stocks
Downgrade for ASX listed fund manager as redemptions pile on
Persistent outflows erode earnings outlook.
stocks
Tesla stock is down nearly 20% this year. Is it a buy ahead of earnings?
Following the rollout of its first autonomous Cybercab, here’s what we expect from Tesla’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,939.20 | 98.80 | 1.12% |
| CAC 40 | 7,934.70 | 61.59 | 0.78% |
| DAX 40 | 25,382.62 | 84.01 | 0.33% |
| Dow JONES (US) | 52,177.69 | 556.21 | 1.08% |
| FTSE 100 | 10,840.35 | 115.49 | 1.08% |
| HKSE | 24,062.72 | 251.45 | -1.03% |
| NASDAQ | 26,713.03 | 20.16 | 0.08% |
| Nikkei 225 | 65,446.08 | 1,020.13 | 1.58% |
| NZX 50 Index | 13,763.37 | 69.43 | -0.50% |
| S&P 500 | 7,744.06 | 25.12 | 0.33% |
| S&P/ASX 200 | 8,807.90 | 88.20 | 1.01% |
| SSE Composite Index | 3,707.48 | 59.75 | -1.59% |